Several possible studies
Story checked
Along with rapid weight loss, patients see other benefits and risks of GLP-1 drugs (opens in a new tab)
cbs12.com · 2026-04-25
Short answer
Several possible studiesNo confirmed study match.
Several papers could fit this story, but none could be confirmed as its source. The claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
Along with rapid weight loss, patients see other benefits and risks of GLP-1 drugs
cbs12.com · 2026-04-25
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Source layer
The 2 papers the story cites
Source study separated from background citations.
The research anchor for the report.
- The study this story reportspresented as the new finding
https://medicine.washu.edu/news/study-identifies-benefits-risks-linked-to-popular-weight-loss-drugs/
- Cited as backgroundpresented as the new finding
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2790392
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 8Not checkedGLP-1 drugs are helping people lose weight rapidly and may also improve several health conditions beyond weight loss.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 8Not checkedLarge clinical trials found that semaglutide reduced major cardiovascular events — including heart attack, stroke and cardiovascular death — by about 20% in overweight or obese adults with cardiovascular disease but no diabetes.View evidenceHide evidence
As statedabout 20%
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 8Not checkedThe article says GLP-1 medications are being used with reported improvement in nonalcoholic fatty liver disease and that the FDA has approved Wegovy injection to treat metabolic-associated steatohepatitis in adults with excessive liver scar tissue.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 8Not checkedThe story says research is underway on whether GLP-1s may affect fertility, pregnancy, and breastfeeding, with limited data so far and recommendations to stop the drugs one to two months before pregnancy.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 8Not checkedA 2025 study by University of Florida researchers found GLP-1 medications were associated with a 17% lower risk of developing 14 obesity-associated cancers.View evidenceHide evidence
As stated17% lower risk
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 8Not checkedTwo global clinical trials of semaglutide for Alzheimer’s disease did not show a significant reduction in cognitive decline versus placebo, although the drug improved some unspecified disease markers.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 7 of 8Not checkedA study of more than 2 million people with diabetes taking these medications found they were associated with reduced risks of seizures and addiction to substances such as alcohol, cannabis, stimulants and opioids.View evidenceHide evidence
As statedmore than 2 million people
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 8 of 8Not checkedRapid weight loss on GLP-1 drugs can also be associated with hair thinning, muscle loss, bone weakening, droopy skin, excess skin, vision problems, dental issues, and gallbladder disease.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Crossref, Europe PMC · 15 candidate papers
A Retrospective Chart Review of Tirzepatide and Semaglutide Use in Prediabetes Management and Cardiometabolic Outcomes in a Rural Primary Care Setting.
Journal of Doctoral Nursing Practice · 2026 · PubMed
Semaglutide and Hospitalizations in Patients with Obesity and Established Cardiovascular Disease
European Journal of Clinical Pharmacy · 2025 · Crossref
Comorbid Cardiovascular-Liver Disease Disparities: Current Understanding and Future Directions.
2026 · Europe PMC
Oral Obesity Medicines in the Era of Cardiovascular-Kidney-Metabolic Syndrome (CKM): Beyond Weight Loss Toward Disease Modification.
Drug Design, Development and Therapy · 2026 · PubMed
Lower risk of MACE and all-cause death in patients initiated on semaglutide 2.4 mg in routine clinical care: Results from the score study (semaglutide effects on cardiovascular outcomes in people with overweight or obesity in the real world)
Archives of Cardiovascular Diseases · 2026 · Crossref